YolTech Therapeutics has received the US Food and Drug Administration (FDA) approval for its investigational new drug (IND) ...

US FDA clears YolTech’s IND application for YOLT-101, an in vivo base editing therapy to treat heterozygous familial hypercholesterolemia: Shanghai, China Monday, June 9, 2025, ...

an in vivo base editing therapy targeting PCSK9 for the treatment of heterozygous familial hypercholesterolemia (HeFH). "The FDA IND clearance marks a significant milestone for YolTech," said Dr ...

Eli Lilly acquires Verve Therapeutics, Inc. for $1B to advance gene-editing therapies like VERVE-102, targeting ASCVD. Click ...

an in vivo base editing therapy targeting PCSK9 for the treatment of heterozygous familial hypercholesterolemia (HeFH). "The FDA IND clearance marks a significant milestone for YolTech," said Dr.

application for YOLT-101 , an in vivo base editing therapy targeting PCSK9 for the treatment of heterozygous familial hypercholesterolemia (HeFH) . "The FDA IND clearance marks a significant ...

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...